Solubilisierung stark lipophiler Arzneistoffe in lipidhaltige ...

Literaturverzeichnis
120. Testosterone: Elecsys® Systems 1010/2010/MODULAR ANALYTICS E170 - product brochure,
Roche diagnostics GmbH, Mannheim, DE, (2001).
121. Taeuber, U., Schroeder, K., Dusterberg, B., und Matthes, H., Absolute bioavailability of
testosterone after oral administration of testosterone-undecanoate and testosterone, Eur. J. Drug
Metab. Pharmacokinet. 11 (1986) 145-149.
122. Farthing, M. J., Vinson, G. P., Edwards, C. R., und Dawson, A. M., Testosterone metabolism by
the rat gastrointestinal tract, in vitro and in vivo, Gut 23 (1982) 226-234.
123. Martin, R. P., Loriaux, D. L., und Farnham, G. S., Enterohepatic cycling of metabolized
testosterone in the male dog, Steroids Suppl. ΙΙ (1965) 149-163.
124. Daggett, P. R., Wheeler, M. J., und Nabarro, J. D., Oral testosterone, a reappraisal, Horm. Res. 9
(1978) 121-129.
125. Foss, G. L., Clinical administration of androgens, Lancet 236 (1939) 502-504.
126. Nieschlag, E., Mauss, J., Coert, A., und Kicovic, P., Plasma androgen levels in men after oral
administration of testosterone or testosterone undecanoate, Acta Endocrinol. 79 (1975) 366-374.
127. Frey, H., Aakvaag, A., Saanum, D., und Falch, J., Bioavailability of oral testosterone in males,
Eur. J. Clin. Pharmacol. 16 (1979) 345-349.
128. Aakvaag, A. und Vogt, J. H., Plasma testosterone values in different forms of testosterone
treatment, Acta Endocrinol. 60 (1969) 537-542.
129. Hamburger, C., Testosterone treatment and 17-ketosteroid excretion. V. Administration of
testosterone per rectum, Acta Endocrinol. 28 (1958) 529-536.
130. Hirschhauser, C., Hopkinson, C. R., Sturm, G., und Coert, A., Testosterone undecanoate: a new
orally active androgen, Acta Endocrinol. 80 (1975) 179-187.
131. Mazer, N. A., New clinical applications of transdermal testosterone delivery in men and women,
J. Contr. Release 65 (2000) 303-315.
132. Altenburger, R. und Kissel, T., The human keratinocyte cell line HaCaT: an in vitro cell culture
model for keratinocyte testosterone metabolism, Pharm. Res. 16 (1999) 766-771.
133. Noguchi, T., Charman, W. N. A., und Stella, V. J., The effect of drug lipophilicity and lipid vehicles
on the lymphatic absorption of various testosterone esters, Int. J. Pharm. 24 (1985) 173-184.
134. Voorspoels, J., Remon, J. P., Eechaute, W., und De Sy, W., Buccal absorption of testosterone
and its esters using a bioadhesive tablet in dogs, Pharm. Res. 13 (1996) 1228-1232.
135. Partsch, C. J., Weinbauer, G. F., Fang, R., und Nieschlag, E., Injectable testosterone
undecanoate has more favourable pharmacokinetics and pharmacodynamics than testosterone
enanthate, Eur. J. Endocrinol. 132 (1995) 514-519.
136. Davidson, D. W., O'Carroll, R., und Bancroft, J., Increasing circulating androgens with oral
testosterone undecanoate in eugonadal men, J. Steroid Biochem. 26 (1987) 713-715.
137. Papadimas, J., Bili, E., Papadopoulou, F., Spanos, E., Tarlatzis, B., Kokkas, B., Pangalos, G.,
Bontis, J., und Mantalenakis, S., Testosterone undecanoate versus mesterolone in hypogonadal
male patients, Epitheor. Klin. Farmakol. Farmakokinet. 10 (1996) 3-8.
138. Shackleford, D. M., Faassen, W. A., Houwing, N., Lass, H., Edwards, G. A., Porter, C. J., und
Charman, W. N., Contribution of lymphatically transported testosterone undecanoate to the
systemic exposure of testosterone after oral administration of two andriol formulations in
conscious lymph duct-cannulated dogs, J. Pharmacol. Exp. Ther. 306 (2003) 925-933.
139. Coert, A., Geelen, J., und De Visser, J., The pharmacology and metabolism of testosterone
undecanoate (TU), a new orally active androgen, Acta Endocrinol. 79 (1975) 789-800.
140. Horst, H. J., Holtje, W. J., Dennis, M., Coert, A., Geelen, J., und Voigt, K. D., Lymphatic
absorption and metabolism of orally administered testosterone undecanoate in man, Klin.
Wochenschr. 54 (1976) 875-879.
cxv